<p>Spruce Biosciences Inc. has announced the appointments of Daven Mody, Pharm.D., as Senior Vice President of Regulatory and Quality, and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations. Mody brings extensive experience in regulatory filings and approvals, while Gagnon has more than 30 years of experience in leading clinical operations for global drug development programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203184321) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Reuters

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares US Pharma

VG Health

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Spruce Biosciences

iShares Global Healthcare

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team